Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

Conference call scheduled today at 8:00 a.m. Pacific Time

SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced its financial results for the first quarter of 2008. For the three months ending March 31, 2008, the Company posted total revenues of $17.0 million and net income of $3.7 million. The revenue includes $10.8 million of revenue earned in the quarter that was attributable to the one-time recognition of the remaining portion of an upfront payment, which had not yet been recognized, related to the Company's collaboration with Novartis. Cash, cash equivalents and short-term investments totaled $30.9 million at March 31, 2008 compared to $39.0 million at December 31, 2007.

"Our team has had a busy and productive quarter," said Mike Grey, President and Chief Executive Officer of SGX. "IND enabling studies are continuing on our MET inhibitor, SGX126, and we now have a better understanding of the nature of the toxicity observed with SGX523. In addition, the progress we are making in our preclinical and late stage discovery programs is encouraging, as we work to build a robust pipeline of targeted oncology therapies. We are also pursuing a number of potential partnering opportunities for our programs, with the objective of expanding our revenue base."

Pipeline Update

MET Program

SGX523: The unexpected toxicity seen in the Phase I studies was compromised kidney function, as evidenced by increased serum creatinine. Analysis of patient samples from the Phase I studies revealed a metabolism profile that differs markedly from that observed in previously conducted preclinical studies. As a result of the observed toxicity, the Company has discontinued further
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), ... promotion of Nick Maroulis, Pharm.D. to the newly created ... , In this position, Dr. Maroulis will continue to ... directors of our multi-site pharmacies as the company expands. ... during that time he has served in many different ...
(Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... developed a new model to predict the optical properties ... help inform the design of tailored nano-structures, and be ... the remote sensing of atmospheric pollutants and the study ... a key role in atmospheric processes as industrial pollutants, ...
... Calif., March 24, 2011 SARcode Corporation announced today ... has been accepted for presentation during the upcoming Association ... being held May 1–May 5, 2011, in Fort Lauderdale, ... therapy that inhibits T-cell mediated inflammation, a key component ...
... Ontario Institute for Cancer Research (OICR) announced today ... of a potentially revolutionary high-throughput screening technology directed ... Smart Well Plate™, developed at the University of ... microfluidics (DMF), a technique that allows manipulation of ...
Cached Biology Technology:UBC researchers develop new model to predict the optical properties of nano-structures 2SARcode Corporation to Present Phase 2 Clinical Data for Dry Eye Candidate at the ARVO2011 Annual Meeting 2SARcode Corporation to Present Phase 2 Clinical Data for Dry Eye Candidate at the ARVO2011 Annual Meeting 3Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs 2Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs 3
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... March issue of Human Nature , women both with ... ratings of photos of men when considering such measures as ... sexual partners spent more time evaluating photos of men, demonstrating ... found between men who had sexual partners and those who ...
... taken on epidemic proportions in developed nations, contributing significantly ... care costs. According to Centers for Disease Control and ... adults and more than 15 percent of children and ... research advances and treatment methods have had little effect ...
... Queen,s University in Kingston, Ontario, Canada, has just received the ... prestigious Premier,s Discovery Awards for 2009. These two prizes follow ... of the Year by The Royal Canadian Geographical Society in ... the Springer book series Developments in Paleoenvironmental Research. ...
Cached Biology News:Single women gaze longer 2Researchers engineer metabolic pathway in mice to prevent diet-induced obesity 2Researchers engineer metabolic pathway in mice to prevent diet-induced obesity 3Springer Series editor John Smol receives two prestigious biology awards 2
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
...
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: